The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies
Description: Technique: ddPCR + targeted NGF, whole exome sequencing
Measure: Identification of the genetic profile in advanced or metastatic NSCLC patients using liquid biopsies (circulating tumoral DNA) Time: 5 yearsDescription: Techniques: ddPCR + targeted NGF, whole exome sequencing
Measure: Identification of genetic biomarkers (or molecular profiles) having a potential predictive value in the treatments response Time: 5 yearsDescription: Techniques: ddPCR + targeted NGF, whole exome sequencing
Measure: Detection of the ALK and ROS1 genes translocations in the circulating DNA Time: 5 yearsDescription: Correlation between mutated allelic fractions or expression's modification with the treatment response. Techniques: ddPCR + targeted NGF, whole exome sequencing
Measure: Evaluation of the liquid biopsies role in the tumoral monitoring Time: 5 yearsDescription: Correlation between transcriptomic and genomic factors and response to immunotherapy. Techniques: ddPCR + targeted NGF, whole exome sequencing
Measure: Evaluation of genomic and transcriptomic factors detectable in the plasma, associated to the immunotherapy response Time: 5 yearsDescription: Techniques: ddPCR + targeted NGF, whole exome sequencing
Measure: Evaluation of the spatial and temporal tumor heterogeneity under targeted therapy treatment Time: 5 yearsDescription: Correlation between miRNAS expression in plasma and treatment's efficacy. Techniques: miRNAs profiling using HTG technology
Measure: Evaluation of the miRNAs' expression in plasma as an epigenetic factor associated to treatments response Time: 5 yearsDescription: Single cell isolation technology
Measure: Circulating tumoral cells isolation and analysis to determine the role of non-genomic and/or phenotypic factors in the treatments response. Time: 5 yearsDescription: Technique: ddPCR + targeted NGF, whole exome sequencing
Measure: Evaluation of the resistance mechanisms to targeted therapies Time: 5 yearsCohort
There is one SNP
It is presently used in routine for detecting the EGFR mutations at diagnosis as well as for searching EGFR T790M mutation for resistant patients. --- T790M ---